United Therapeutics (UTHR) CFO sells 10k shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction. On April 30, 2026, he exercised 10,000 stock options for Common Stock at a strike price of $135.42 per share and then sold 10,000 shares in a series of open-market trades at prices reported between $569.24 and $578.76 per share.

These actions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025. After the transactions, he directly owned 18,876 shares of United Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($5,726,062)

Net Sell 13 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 10,000 shs ($5.73M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	10,000	$0.00	--
Exercise	Common Stock	10,000	$135.42	$1.35M
Sale	Common Stock	262	$569.2437	$149K
Sale	Common Stock	484	$570.1912	$276K
Sale	Common Stock	2,940	$571.2313	$1.68M
Sale	Common Stock	3,034	$572.0028	$1.74M
Sale	Common Stock	880	$573.0046	$504K
Sale	Common Stock	887	$574.0653	$509K
Sale	Common Stock	273	$574.9643	$157K
Sale	Common Stock	486	$576.2407	$280K
Sale	Common Stock	336	$577.2372	$194K
Sale	Common Stock	378	$578.0696	$219K
Sale	Common Stock	40	$578.76	$23K

Holdings After Transaction: Stock Option — 42,500 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)

Footnotes (1)

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $576.75 to $577.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $577.76 to $578.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.58 to $569.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $569.58 to $570.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $570.61 to $571.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.61 to $572.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $572.61 to $573.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $573.61 to $574.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.61 to $575.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.73 to $576.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 10,000 shares Option strike price: $135.42 per share Shares sold: 10,000 shares +5 more

8 metrics

Options exercised 10,000 shares Stock options for Common Stock exercised on April 30, 2026

Option strike price <money>$135.42</money> per share Exercise price for 10,000 stock options

Shares sold 10,000 shares Common Stock sold in open-market transactions on April 30, 2026

Highest reported sale price <money>$578.76</money> per share Weighted average price for one sale tranche

Lowest reported sale price <money>$569.24</money> per share Weighted average price for another sale tranche

Shares held after transactions 18,876 shares Directly owned Common Stock following all reported trades

Rule 10b5-1 plan date October 31, 2025 Date the trading plan governing these trades was entered into

Option expiration date March 15, 2027 Expiration date for the exercised stock options

Key Terms

Rule 10b5-1 trading plan, weighted average price, stock options, derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above reflects the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock options financial

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/30/2026		M⁽¹⁾		10,000	A	$135.42	28,876	D
Common Stock	04/30/2026		S⁽¹⁾		262	D	$569.2437⁽²⁾	28,614	D
Common Stock	04/30/2026		S⁽¹⁾		484	D	$570.1912⁽³⁾	28,130	D
Common Stock	04/30/2026		S⁽¹⁾		2,940	D	$571.2313⁽⁴⁾	25,190	D
Common Stock	04/30/2026		S⁽¹⁾		3,034	D	$572.0028⁽⁵⁾	22,156	D
Common Stock	04/30/2026		S⁽¹⁾		880	D	$573.0046⁽⁶⁾	21,276	D
Common Stock	04/30/2026		S⁽¹⁾		887	D	$574.0653⁽⁷⁾	20,389	D
Common Stock	04/30/2026		S⁽¹⁾		273	D	$574.9643⁽⁸⁾	20,116	D
Common Stock	04/30/2026		S⁽¹⁾		486	D	$576.2407⁽⁹⁾	19,630	D
Common Stock	04/30/2026		S⁽¹⁾		336	D	$577.2372⁽¹⁰⁾	19,294	D
Common Stock	04/30/2026		S⁽¹⁾		378	D	$578.0696⁽¹¹⁾	18,916	D
Common Stock	04/30/2026		S⁽¹⁾		40	D	$578.76	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$135.42	04/30/2026		M⁽¹⁾			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	42,500	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $568.58 to $569.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $569.58 to $570.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $570.61 to $571.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $571.61 to $572.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $572.61 to $573.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $573.61 to $574.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $574.61 to $575.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $575.73 to $576.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $576.75 to $577.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $577.76 to $578.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report?

CFO James Edgemond reported exercising 10,000 United Therapeutics stock options and selling 10,000 shares of Common Stock. The sales occurred in multiple open-market trades on April 30, 2026, at weighted average prices in the high $560s to high $570s per share.

At what price did the UNITED THERAPEUTICS (UTHR) CFO exercise his stock options?

He exercised 10,000 stock options at a strike price of $135.42 per share. These options converted into 10,000 shares of United Therapeutics Common Stock before being sold in separate open-market transactions disclosed in the same Form 4 filing.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO sell, and at what prices?

He sold 10,000 shares of United Therapeutics Common Stock in 11 open-market transactions. Reported weighted average sale prices for these trades range from about $569.24 to $578.76 per share, with several trades executed in narrower price bands disclosed in the footnotes.

How many UNITED THERAPEUTICS (UTHR) shares does the CFO hold after these transactions?

Following the option exercise and subsequent sales, CFO James Edgemond directly holds 18,876 shares of United Therapeutics Common Stock. This post-transaction ownership figure is explicitly stated as the total shares beneficially owned after the reported trades.

Were the UNITED THERAPEUTICS (UTHR) CFO’s trades part of a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that the stock option exercise and subsequent sale of shares were executed pursuant to a Rule 10b5-1 trading plan. That plan was entered into by the reporting person on October 31, 2025, indicating the trades were pre-arranged.

What do the weighted average price footnotes mean in the UTHR Form 4?

Several transactions were executed in multiple trades within specified price ranges, so the Form 4 reports a single weighted average price. The footnotes explain this and note the CFO will provide detailed trade counts and prices to the SEC, issuer, or security holders upon request.